Sunovion scores on PhIII Parkinson's study, shooting for showdown with Acorda; Puma out-licenses neratinib to Israeli biotech
→ Sunovion Pharmaceuticals has posted positive top-line data from their Phase III study for OFF episodes of Parkinson’s disease. According to researchers apomorphine hit the primary: a statistically significant mean reduction in the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III score. They added that the drug also scored on a key secondary. Sunovion now plans to hustle the drug to the FDA soon, which may well set up a confrontation with a rival drug from the struggling Acorda $ACOR, now rumored to be on the sales block.
→ The EMA may be shutting the door to Puma Biotechnology’s neratinib, but that hasn’t stopped the company $PBYI from trying to commercialize the drug (also known as Nerlynx) outside the US. Israel’s Medison Pharma is the newest partner of the Los Angeles-based biotech, having inked an exclusive licensing deal to seek regulatory approval for and commercialize the breast cancer treatment. Medison execs say they expect to receive approval from the Israeli Ministry of Health in 2019.
→ Entera Bio, the Jerusalem-based company that specializes in oral delivery of injectables, has postponed the $55 million IPO that it proposed earlier this month. It had planned to offer 5 million shares at a price range of $10 to $12, listing as $ENTX.